Daiichi Sankyo

Medco Research Institute announced this week that it is sponsoring a study to determine the optimal antiplatelet treatment for patients who are also using a proton pump inhibitor for the treatment of heartburn. The study will involve genetic testing to establish which patients can respond to Plavix.

Daiichi Sankyo is the first collaborator to use Morphosys' HuCAL Platinum antibody library for new drug discovery in infectious diseases.

Medco's study will examine whether the 70 to 75 percent of patients who are "extensive metabolizers" of Bristol-Myers Squibb's Plavix will have "comparable outcomes" to patients taking Eli Lilly's more expensive Effient.